October 13, 2014 | Israeli cancer diagnostics company Micromedic announced the trial of its product for detecting cervical cancer at the Beijing Military Hospital. The product proved successful in the trial at marking the cancer cells, making the diagnostic process more effective. However, Micromedic also reported that its current distributor in China is unable to handle the anticipated sales volume, forcing the company to consider other possibilities for distribution in the country. China and India are currently the major markets for Micromedic’s product because it is the only effective diagnostic test in the commercial stage. Micromedic is the cancer diagnosis technology unit of Bio-Light Israeli Life Science Investments, which owns 31 percent of the company.